Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist

• Published in: Nippon Hinyokika Gakkai zasshi Vol. 100; no. 7; p. 686
• Main Authors: Tsujimura, Akira, Takao, Tetsuya, Uchida, Kinya, Yamamoto, Keisuke, Fukuhara, Shinichiro, Nakayama, Jiro, Ueda, Tomohiro, Hirai, Toshiaki, Kiuchi, Hiroshi, Miyagawa, Yasushi, Takahashi, Toru, Kojimaan, Yasuyuki, Okuyama, Akihiko
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.11.2009
• Subjects: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists - administration & dosage; Adrenergic alpha-Antagonists - adverse effects; Aged; Aged, 80 and over; Benzhydryl Compounds - administration & dosage; Benzhydryl Compounds - adverse effects; Cresols - administration & dosage; Cresols - adverse effects; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists - administration & dosage; Muscarinic Antagonists - adverse effects; Phenylpropanolamine - administration & dosage; Phenylpropanolamine - adverse effects; Prostatic Hyperplasia - complications; Quality of Life; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive - drug therapy; Urinary Bladder, Overactive - etiology
• ISSN: 0021-5287
• DOI: 10.5980/jpnjurol.100.686

The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH) together with overactive bladder (OAB) has been controversial. The purpose of this study was to evaluate the effect of tolterodine combined with alpha1-AR antagonist for patients with BPH and OAB after insufficient efficacy by monotherapy with alpha1-AR antagonist. The adverse event of this combined therapy was also assessed. The study included 47 patients with BPH, whose OAB symptom persisted (OAB symptom score; OABSS > or =3) after monotherapy with alpha1-AR antagonist for more than 4 weeks. The mean age was 72.9 years and the mean prostate volume was 29.8 ml. Four mg/day of tolterodine with alpha-AR antagonist was administered for 8 weeks to patients. International prostate symptom score (IPSS), quality of life (QOL) index, OABSS, King's Health Questionnaire (KHQ) and residual urine volume (RUV) were assessed before and after combined therapy. Six patients were dropped out from this study because of dry mouth, constipation, onset of other disease and insufficient efficacy by self-judgment. IPSS (from 15.1 +/- 6.8 to 11.0 +/- 7.9; P < 0.01), QOL index (from 4.3 +/- 1.1 to 3.6 +/- 1.3; P < 0.01) and OABSS (from 7.0 +/- 3.0 to 5.4 +/- 2.9; P < 0.01) of 41 patients improved significantly by combined therapy. The storage symptom of IPSS subscore improved significantly (from 8.0 +/- 2.9 to 6.5 +/- 2.8; P < 0.01), whereas the voiding symptom did not improve. Regarding KHQ, the score of 3 domains (impact on life, role limitation, and physical limitation) improved significantly (P < 0.05). RUV did not change and no serious adverse event including urinary retention was found in this study. This study reveals that the combined therapy of alpha-AR antagonist and tolterodine represents an effective and safe treatment modality for patients with BPH and OAB, whose OAB symptom was not improved by antecedent monotherapy with alpha-AR antagonist.